Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.

Blood - 1 Jan 2005

Stone Richard M, DeAngelo Daniel J, Klimek Virginia, Galinsky Ilene, Estey Eli, Nimer Stephen D, Grandin Wilson, Lebwohl David, Wang Yanfeng, Cohen Pamela, Fox Edward A, Neuberg Donna, Clark Jennifer, Gilliland D Gary, Griffin James D

Abstract excerpt

Leukemic cells from 30% of patients with acute myeloid leukemia (AML) have an activating mutation in the FLT3 (fms-like tyrosine kinase) gene, which represents a target for drug therapy. We treated 20 patients, each with mutant FLT3 relapsed/refractory AML or high-grade myelodysplastic syndrome and not believed to be candidates for chemotherapy, with an FLT3 tyrosine kinase inhibitor, PKC412...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Cell Count
Share to Bone Marrow

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Enzyme Activation

Share to fms-Like Tyrosine Kinase 3

Share to Leukemia, Myeloid, Acute

Share to Phosphotyrosine

Share to Receptor Protein-Tyrosine Kinases

Share to Staurosporine

Source

Identifiers

PMID: 15345597
DOI: 10.1182/blood-2004-03-0891

Genes

FLT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.PMID 15345597Read ↗

Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML).Semantic proximity Read ↗

Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.Semantic proximity Read ↗

Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.Semantic proximity Read ↗

The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases.Semantic proximity Read ↗

FLT3 tyrosine kinase inhibitors.Semantic proximity Read ↗

Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domainSemantic proximity Read ↗

FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignanciesSemantic proximity Read ↗

The FLT3 inhibitor PKC412 exerts differential cell cycle effects on leukemic cells depending on the presence of FLT3 mutations.Semantic proximity Read ↗

Divergent cytotoxic effects of PKC412 in combination with conventional antileukemic agents in FLT3 mutation-positive versus -negative leukemia cell lines.Semantic proximity Read ↗

Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells.Semantic proximity Read ↗

PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder.Semantic proximity Read ↗

FLT3 inhibition in acute myeloid leukaemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.